» Authors » David Ivancic

David Ivancic

Explore the profile of David Ivancic including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 22
Citations 356
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Lee O, Ivancic D, Allu S, Shidfar A, Kenney K, Helenowski I, et al.
Cancer Chemother Pharmacol . 2015 Nov; 76(6):1235-46. PMID: 26560487
Purpose: Women at high risk of breast cancer and those with carcinoma in situ need non-toxic, well-tolerated preventive interventions. One promising approach is drug delivery through the breast skin (local...
12.
Lee O, Page K, Ivancic D, Helenowski I, Parini V, Sullivan M, et al.
Clin Cancer Res . 2014 Jul; 20(14):3672-82. PMID: 25028506
Purpose: Local transdermal therapy to the breast may achieve effective target-organ drug delivery, while diminishing systemic effects. We conducted a randomized, double-blind, placebo-controlled phase II trial comparing transdermal 4-hydroxytamoxifen gel...
13.
Hu H, Wang J, Gupta A, Shidfar A, Branstetter D, Lee O, et al.
Breast Cancer Res Treat . 2014 Jul; 146(3):515-23. PMID: 25007964
The receptor activator of nuclear factor-κB ligand (RANKL) acts as a paracrine factor in progesterone-induced mammary epithelial proliferation and tumorigenesis. This evidence comes mainly from mouse models. Our aim was...
14.
Lee O, Ivancic D, Chatterton Jr R, Rademaker A, Khan S
Breast Cancer (Dove Med Press) . 2013 Dec; 3:61-70. PMID: 24367176
Purpose: Oral tamoxifen, a triphenylethylene (TPE), is useful for breast cancer prevention, but its adverse effects limit acceptance by women. Tamoxifen efficacy is related to its major metabolites 4-hydroxytamoxifen (4-OHT)...
15.
Wang J, Scholtens D, Holko M, Ivancic D, Lee O, Hu H, et al.
Cancer Prev Res (Phila) . 2013 Mar; 6(4):321-30. PMID: 23512947
Risk biomarkers that are specific to estrogen receptor (ER) subtypes of breast cancer would aid the development and implementation of distinct prevention strategies. The contralateral unaffected breast of women with...
16.
Khan S, Chatterton R, Michel N, Bryk M, Lee O, Ivancic D, et al.
Cancer Prev Res (Phila) . 2012 Feb; 5(2):309-19. PMID: 22307566
Soy isoflavone consumption may protect against breast cancer development. We conducted a phase IIB trial of soy isoflavone supplementation to examine its effect on breast epithelial proliferation and other biomarkers...
17.
Chatterton Jr R, Khan S, Heinz R, Ivancic D, Lee O
Cancer Epidemiol Biomarkers Prev . 2010 Jan; 19(1):275-9. PMID: 20056648
Previous studies have shown that progesterone concentrations in serum and nipple aspirate fluid (NAF) are significantly correlated in premenopausal women, but estradiol concentrations are not. We therefore sought to ascertain...
18.
Tang Y, Clayburgh D, Mittal N, Goretsky T, Dirisina R, Zhang Z, et al.
Am J Pathol . 2009 Dec; 176(1):158-67. PMID: 20008138
In inflammatory bowel disease (IBD), aberrant activation of innate and adaptive immune responses enhances mucosal permeability through mechanisms not completely understood. To examine the role of epithelial nuclear factor (NF-kappaB)...
19.
Khan S, Lankes H, Patil D, Bryk M, Hou N, Ivancic D, et al.
Cancer Prev Res (Phila) . 2009 Feb; 2(3):265-73. PMID: 19223577
Effective methods of serial epithelial sampling to measure breast-specific biomarkers will aid the rapid evaluation of new preventive interventions. We report here a proof-of-principle phase 2 study to assess the...
20.
Zaichuk T, Ivancic D, Scholtens D, Schiller C, Khan S
J Steroid Biochem Mol Biol . 2007 Jun; 105(1-5):76-84. PMID: 17596930
Steroid sulfatase (STS) increases the pool of precursors of biologically active steroids, thereby playing an important role in breast cancer development. Mechanisms that control STS expression remain poorly understood. In...